Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide.
Fiche publication
Date publication
octobre 2020
Journal
Acta oncologica (Stockholm, Sweden)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana, Pr DECONINCK Eric, Dr DAGUINDAU Etienne
Tous les auteurs :
Chevallier P, Berceanu A, Peterlin P, Garnier A, Le Bourgeois A, Imbert BM, Daguindau E, Mahé B, Dubruille V, Blin N, Touzeau C, Gastinne T, Lok A, Tessoulin B, Vantyghem S, Desbrosses Y, Bressollette C, Duquesne A, Eveillard M, Le Bris Y, Dormoy A, Malugani C, Deconinck E, Moreau P, Le Gouill S, Béné MC, Guillaume T
Lien Pubmed
Résumé
The impact of acute graft versus host disease (GVHD) on survivals for patients receiving a haploidentical allogeneic stem-cell transplant (Allo-SCT) with peripheral blood stem-cells (PBSC) complemented by post-transplant cyclophosphamide (PTCY) is ill-known.
Mots clés
ATG, Allogeneic stem cell transplantation, GVHD, PBSC, PTCY, RIC, clofarabine, haplo-identical, immune
Référence
Acta Oncol. 2020 Oct 28;:1-9